Why do some people accumulate Alzheimer's plaques yet never develop dementia, while others decline? A new study points to a hidden tipping point inside the brain's immune cells.
Scientists at VIB-KU Leuven and collaborators, writing in Nature Medicine, mapped the behavior of microglia — the brain's resident immune cells — across donated human brain tissue, including from cognitively healthy centenarians.
The switch they found
Early in the disease, microglia respond to amyloid-β plaques in a relatively contained, inflammatory way. But the team identified a critical transition where microglia shift into an antigen-presenting state tied to tau pathology and neurodegeneration. Whether microglia cross that threshold — or stay separated from the damaging cascade — appears to help determine whether plaques progress to dementia.
The work, “entirely based on human donor material, provides insight into one type of resilience mechanism,” said Prof. Bart De Strooper of VIB-KU Leuven.
Why it matters
Most Alzheimer's drugs aim to clear plaques. This research suggests an alternative: keep microglia on the “resilient” side of the tipping point — potentially via pathways like TREM2 — to extend the brain's natural defenses. It's early, mechanistic science built on postmortem tissue, not a therapy, but it reframes where the fight against dementia might be won.